Researchers pinpoint exactly where each building block sits in HIV

November 3, 2014, European Molecular Biology Laboratory
Surprisingly, the building blocks in immature HIV (centre) are arranged differently from those of immature Mason-Pfizer Monkey Virus (left). To form the mature virus, HIV’s building blocks take on yet another arrangement (right). Credit: EMBL/F.Schur

Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus. The study, published online today in Nature, reveals that the building blocks of the immature form of HIV are arranged in a surprising way.

"The structure is definitely different from what we'd expected," says John Briggs from EMBL, who led the work. "We assumed that retroviruses like HIV and Mason-Pfizer Monkey Virus would have similar structures, because they use such similar building blocks, but it turns out that their immature forms are surprisingly different from each other. At this point, we don't really know why."

Briggs and colleagues used cryo-electron microscopy to study the protein lattice that surrounds the virus' genetic material. After infecting one of the cells in our immune system, HIV replicates, producing more copies of itself, each of which has to be assembled from a medley of viral and cellular components into an immature virus. This is the form that leaves the cell. The protein that make up the virus are then rearranged into the virus' mature form, which can infect other cells.

The first cryo-electron microscopy images of immature HIV, obtained at EMBL in the 1990s, surprised researchers by showing that the virus did not have a regular symmetrical structure, as had been assumed. That meant it was going to be difficult to get a detailed picture of the structure of its protein lattice. Two decades on, by optimising both how data is collected at the microscope and how it is analysed, Florian Schur, a PhD student in Briggs' lab, has now achieved an unprecedentedly detailed structure.

With this structure in hand, scientists have a basis to probe further. They can use it to decide where to focus efforts for achieving the even greater detail needed to explore potential drug targets, for instance. It will also enable researchers to understand how mutations might influence how the virus assembles. And the techniques themselves can be applied to a variety of questions.

"This approach offers so many possibilities," says Schur. "You can look at other viruses, of course, but also at complexes and proteins inside cells, with a whole new level of detail."

In future, the EMBL scientists will use the approach to look at other viruses and at the vesicles that transport material inside cells. They also aim to push the techniques even further, to allow them to see other parts of the viral proteins that are currently beyond their reach, but which they suspect play an important role in HIV maturation.

"In the long term, we'd also like to investigate how drugs which are known to inhibit assembly and maturation actually work," Briggs concludes.

Explore further: Scientists believe they can identify which HIV strains cause infection

More information: Schur, F.K.M., Hagen, W.J.H., Rumlová, M., Ruml, T., Müller, B., Kräusslich, H. & Briggs, J.AG. "The structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution." Published online in Nature, 2 November 2014. DOI: 10.1038/nature13838.

Related Stories

Scientists believe they can identify which HIV strains cause infection

July 21, 2014
(Medical Xpress)—HIV-infected people carry many different HIV viruses and all have distinct personalities—some much more vengeful and infectious than others.

'Transformer' protein makes different sized transport pods

May 25, 2012
These spheres may look almost identical, but subtle differences between them revealed a molecular version of the robots from Transformers. Each sphere is a vesicle, a pod that cells use to transport materials between different ...

Recommended for you

New HIV therapy reduces virus, boosts immunity in drug-resistant patients

August 15, 2018
In a study, a new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy ...

In choosing care, HIV patients in Zambia prefer kindness over convenience

August 15, 2018
As a healthcare patient, what would you sacrifice for a provider with a nice—rather than rude—attitude? For HIV patients in Zambia, the answer may surprise you.

Details of HIV-1 structure open door for potential therapies

August 9, 2018
New research provides details of how the structure of the HIV-1 virus is assembled, findings that offer potential new targets for treatment.

Researchers uncover potential new drug targets in the fight against HIV

August 7, 2018
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that ...

Naltrexone helps HIV positive individuals reduce heavy alcohol use

August 7, 2018
Extended-release naltrexone—an injection that decreases heavy drinking in the general population when taken in conjunction with counseling—appears to help HIV-positive individuals reduce their number of heavy drinking ...

EU door opens for generic version of AIDS medicine Truvada

July 26, 2018
Patient associations on Thursday lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.